Considering the well‐documented positive impact of immune cell therapy on the clinical outcomes of gliomas (Sokratous et al., 2017), these findings suggest that TRIM22 may serve as a promising indicator for assessing the potential efficacy of immunotherapy in glioma treatment. Here, TRIM22 is linked to central nervous system cancer.